With a revenue increase of 55.5% in the first quarter 2026, year on year to cumulative value of $51 million, Kymera Therapeutics Inc 's revenue per employee grew on a trailing twelve months basis to $ 216,286, this is below the company average. Within the Healthcare sector Employees of 235 other companies have achieved higher revenue per employee. While Kymera Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 1347 to 1841. Kymera Therapeutics Inc has 238 employees.
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer Amidst Milestones and Financial RealitiesKymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering biopharmaceutical company headquartered in Watertown, Massachusetts, has recently announced the appointment of Noah Goodman, M.B.A. as its new Chief Business Officer. This strategic move comes at a crucial juncture for Kymera, which is making notable advancements in the realm of oral small molecule degrader medicines targeted at immunological diseases. With over a decade of diverse experience in the life sciences sector, Goodman’s expertise is expected to enhance Kymera’s business development strategies significantly. In his new role, Goodman will lead the company’s efforts to cultivate partnerships, drive growth opportunities, and navigate the often volatile landscape of biopharmaceutical commercialization. His strategic acumen is particularly vital as the company embarks on ambitious initiatives in 2025 and beyond.Earlier this year, Kymera articulated its key objectives and strategies aimed at advancing its industry-leading portfolio of oral immunology programs. Notably, the company has achieved a significant milestone by receiving FDA clearance for its Investigational New Drug (IND) application for KT-621, marking it as the first oral STAT6 degrader that targets Th2-mediated diseases. This breakthrough highlights Kymera’s commitment to innovation in therapeutic approaches, ideally positioning it to lead the charge in a nascent field.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
